Adderall Gets Added Approval

Shire says the drug is cleared for adolescents aged 13 to 17 with ADHD.
Publish date:

Shire Pharmaceuticals


said the Food and Drug Administration approved Adderall XR as a once-daily treatment for adolescents aged 13 to 17 with attention deficit hyperactivity disorder.

Since October 2001, the drug has been available in the U.S. for treating children aged 6 to 12 and since August 2004 for adults 18 and older. Adderall XR is currently the most commonly prescribed brand of ADHD medication in the U.S., Shire said.

ADHD affects about 3% to 7% of all school-age children and is considered the most commonly diagnosed psychiatric disorder in children and adolescents, Shire said in a press release Friday.

The condition is a neurological brain disorder that appears as a persistent pattern of inattention or hyperactivity-impulsivity that is more frequent and severe than is typically observed in individuals at a comparable age.

The American depositary shares of the U.K.-based pharmaceutical company were up 3 cents to $33.91.